Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010;21(1):1-14.
doi: 10.3233/JAD-2010-1414.

Neuroinflammation in Alzheimer's disease: mechanisms, pathologic consequences, and potential for therapeutic manipulation

Kenneth Hensley  1
Affiliations
Review

Neuroinflammation in Alzheimer's disease: mechanisms, pathologic consequences, and potential for therapeutic manipulation

Kenneth Hensley. J Alzheimers Dis. 2010.

Abstract

The concept of neuroinflammation has evolved over the past two decades from an initially controversial viewpoint to its present status as a generally accepted idea whose mechanisms and consequences are still actively under research and debate, particularly with regard to Alzheimer's disease (AD). This review summarizes the current status of neuroinflammation research as it specifically relates to AD. Neuroinflammation is discussed mechanistically with emphasis on the role of redox signal transduction linked to the activation of central nervous system-relevant innate immune pathways. Redox signaling is presented both as a causal factor and a consequence of sustained neuroinflammation. Functional relationships are discussed that connect distinct neuroinflammatory components such as cytokines, eicosanoids, classic AD pathology (amyloid plaques and neurofibrillary tangles), and the recently emergent notion of "damage-associated molecular patterns". The interaction of these paracrine factors likely can produce positive as well as negative effects on the AD brain, ranging from plaque clearance by microglia in the short term to glial dysfunction and neuronal compromise if the neuroinflammation is chronically sustained and unmitigated. Recent disappointments in AD clinical trials of anti-inflammatory drugs are discussed with reference to possible explanations and potential avenues for future pharmacological approaches to the disease.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
A Representation of the glutathionylation cycle of protein regulation through glutathione conjugation, a principal means of redox signal transduction control at the level of post-translational modification. The protein modified by glutathionylation is typically (but not always) a phosphatase containing an especially nucleophilic cysteine. B) A broader view of the relationships amongst the phenomena of redox signal transduction, oxidative stress, and neuroinflammation. The hypothetical cell in this schematic is intended to be a microglial or astrocyte, which would be involved in reciprocal autocrine and paracrine signaling with ambient neurons and other glial cell types. The glutathionylation cycle depicted in panel A would be implicit in panel B, along with other types of reversible and irreversible protein post-translational modifications that mediate redox signal transduction mechanisms. In the context of AD specifically, perturbations in the intracellular signaling pathways would lead to aberrant phosphorylation, protein aggregation, and processing that could contribute ultimately to both NFTs and amyloid plaque deposition. These phenomena would superimpose upon and interact with the neuroinflammatory forces depicted explicitly in panel B.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. McGeer PL, Rogers J, McGeer EG, Sibley J. Anti-inflammatory drugs and Alzheimer’s disease? Lancet. 1990;335:1037. - PubMed
    1. Rogers J. The inflammatory response in Alzheimer’s disease. J Periodontol. 2008;79:1535–1543. - PubMed
    1. McGeer PL, McGeer EG. NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies. Neumbiol Aging. 2007;88:639–647. - PubMed
    1. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer’s disease: A review of 17 epidemiologic studies. Neurology. 1996;47:425–432. - PubMed
    1. In’t Veld BA, Ruitenberg A, Hofman A, Launer LJ, vn Duijn CM, Stijnen T, Breteler MM, Strieker BH. Nonsteroidal anti-inflammatory drugs and the risk of Alzheimer’s disease. N Engl J Med. 2001;345:1515–1521. - PubMed

Publication types

MeSH terms